Title | Phase 2 Multi-center Study of Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) w/Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs) |
---|---|
Disease/Condition | Lung Cancer,Lung Diseases,Carcinoma,Neoplasms |
Eligibility Criteria | Click here for eligibility requirements |
Principal Investigator | Balazs Halmos, MD |
Contact Name | Remy Lambert |
Contact Email | rlambert@montefiore.org |
IRB/Protocol Number | 2017-8355 |
Status | Active/Enrolling |
Adult Clinical Trial | Yes |
Pediatric Clinical Trial | No |
Sub-Specialty | Medical and Hematologic Oncology - Lung |